Publication Cover
AIDS Care
Psychological and Socio-medical Aspects of AIDS/HIV
Volume 19, 2007 - Issue 1
102
Views
23
CrossRef citations to date
0
Altmetric
Original Articles

Influence of the type of pegylated interferon on the onset of depressive and neuropsychiatric symptoms in HIV-HCV coinfected patients

, , , , , , , , , , & show all
Pages 138-145 | Published online: 10 Apr 2007

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Renata Fialho, Marco Pereira, Jennifer Rusted & Richard Whale. (2017) Depression in HIV and HCV co-infected patients: a systematic review and meta-analysis. Psychology, Health & Medicine 22:9, pages 1089-1104.
Read now
Lorraine Sherr, Claudine Clucas, Richard Harding, Elissa Sibley & Jose Catalan. (2011) HIV and Depression – a systematic review of interventions. Psychology, Health & Medicine 16:5, pages 493-527.
Read now

Articles from other publishers (21)

Eneko Sansinenea, Nagore Asla, Arrate Agirrezabal, Maria Jose Fuster-Ruiz-de-Apodaca, Alexander Muela & Maite Garaigordobil. (2019) Being Yourself and Mental Health: Goal Motives, Positive Affect and Self-Acceptance Protect People with HIV from Depressive Symptoms. Journal of Happiness Studies 21:2, pages 593-612.
Crossref
Evan B. Cunningham, Behzad Hajarizadeh, Olav Dalgard, Janaki Amin, Margaret Hellard, Graham R Foster, Philip Bruggmann, Brian Conway, Markus Backmund, Geert Robaeys, Tracy Swan, Philippa S. Marks, Sophie Quiene, Tanya L Applegate, Martin Weltman, David Shaw, Adrian Dunlop, Julie Bruneau, Håvard Midgard, Stefan Bourgeois, Maria Christine Thurnheer, Gregory J Dore & Jason Grebely. (2017) Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study. BMC Infectious Diseases 17:1.
Crossref
Renata Fialho, Marco Pereira, Neil Harrison, Jennifer Rusted & Richard Whale. (2017) Co-infection with HIV associated with reduced vulnerability to symptoms of depression during antiviral treatment for hepatitis C. Psychiatry Research 253, pages 150-157.
Crossref
Jeffrey J. Weiss, Ioannis Konstantinidis, Anna Boueilh, Daniel S. Fierer, Donald Gardenier, Mark G. Barber, Tony Kang, Anna Kress, Katherine Ericson, Marlene C. Lira, Marina P. Yostos, Hillary R. Bogner, Juan P. Wisnivesky & Christina M. Wyatt. (2016) Illness Perceptions, Medication Beliefs, and Adherence to Antiretrovirals and Medications for Comorbidities in Adults With HIV Infection and Hypertension or Chronic Kidney Disease. JAIDS Journal of Acquired Immune Deficiency Syndromes 73:4, pages 403-410.
Crossref
Marta Martin-Subero & Crisanto Diez-Quevedo. (2016) Mental disorders in HIV/HCV coinfected patients under antiviral treatment for hepatitis C. Psychiatry Research 246, pages 173-181.
Crossref
Edana Cassol, Vikas Misra, Susan Morgello, Gregory D. Kirk, Shruti H. Mehta & Dana Gabuzda. (2015) Altered Monoamine and Acylcarnitine Metabolites in HIV-Positive and HIV-Negative Subjects With Depression. JAIDS Journal of Acquired Immune Deficiency Syndromes 69:1, pages 18-28.
Crossref
Alasdair Timothy Llewelyn Rathbone, Surejini Tharmaradinam, Shucui Jiang, Michel P. Rathbone & Dinesh A. Kumbhare. (2015) A review of the neuro- and systemic inflammatory responses in post concussion symptoms: Introduction of the “post-inflammatory brain syndrome” PIBS. Brain, Behavior, and Immunity 46, pages 1-16.
Crossref
Maria Pizzirusso, Jenny Lin, Cory Head, Sue M. Marcus, Samia Ahmed, Norbert Bräu & Jeffrey J. Weiss. (2014) Impact of Hepatitis C Treatment Initiation on Adherence to Concomitant Medications. Journal of the Association of Nurses in AIDS Care 25:1, pages 23-31.
Crossref
D. M. Evon, D. A. Esserman, J. E. Bonner, T. Rao, M. W. Fried & C. E. Golin. (2013) Adherence to PEG/ribavirin treatment for chronic hepatitis C: prevalence, patterns, and predictors of missed doses and nonpersistence. Journal of Viral Hepatitis 20:8, pages 536-549.
Crossref
Nicolas Flori, Natalie Funakoshi, Yohan Duny, Jean-Christophe Valats, Michael Bismuth, Dimitri Christophorou, Jean-Pierre Daurès & Pierre Blanc. (2013) Pegylated Interferon-α2a and Ribavirin versus Pegylated Interferon-α2b and Ribavirin in Chronic Hepatitis C. Drugs 73:3, pages 263-277.
Crossref
J. E. Bonner, D. Esserman & D. M. Evon. (2011) Reliability and validity of a self‐efficacy instrument for hepatitis C antiviral treatment regimens. Journal of Viral Hepatitis 19:5, pages 316-326.
Crossref
Jason Grebely, Gail V. Matthews, Margaret Hellard, David Shaw, Ingrid van Beek, Kathy Petoumenos, Maryam Alavi, Barbara Yeung, Paul S. Haber, Andrew R. Lloyd, John M. Kaldor & Gregory J. Dore. (2011) Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users. Journal of Hepatology 55:1, pages 76-85.
Crossref
Patrizia Burra, Giacomo Germani, Francesca Gnoato, Silvia Lazzaro, Francesco Paolo Russo, Umberto Cillo & Marco Senzolo. (2011) Adherence in liver transplant recipients. Liver Transplantation 17:7, pages 760-770.
Crossref
Ashwani K. Singal, Sarat C. Jampana & Bhupinderjit S. Anand. (2011) Comment on a systematic review of randomized trials of peginterferon alpha-2a versus peginterferon alpha-2b in chronic hepatitis C. Hepatology 53:6, pages 2151-2151.
Crossref
Patrick Marcellin, Michel Chousterman, Thierry Fontanges, Denis Ouzan, Michel Rotily, Marina Varastet, Jean-Philippe Lang, Pascal Melin & Patrice Cacoub. (2011) Adherence to treatment and quality of life during hepatitis C therapy: a prospective, real-life, observational study. Liver International 31:4, pages 516-524.
Crossref
Glenn Wagner, Karen Chan Osilla, Jeffrey Garnett, Bonnie Ghosh-Dastidar, Laveeza Bhatti, Matthew Bidwell Goetz & Mallory Witt. (2011) Patient Characteristics Associated with HCV Treatment Adherence, Treatment Completion, and Sustained Virologic Response in HIV Coinfected Patients. AIDS Research and Treatment 2011, pages 1-7.
Crossref
Lauren A. Beste, George N. Ioannou, Meaghan S. Larson, Michael Chapko & Jason A. Dominitz. (2010) Predictors of Early Treatment Discontinuation Among Patients With Genotype 1 Hepatitis C and Implications for Viral Eradication. Clinical Gastroenterology and Hepatology 8:11, pages 972-978.
Crossref
L. Michel, V. Villes, F. Dabis, B. Spire, M. Winnock, M.-A. Loko, I. Poizot-Martin, M. A. Valantin, P. Bonnard, D. Salmon-Céron & M. P. Carrieri. (2009) Role of treatment for depressive symptoms in relieving the impact of fatigue in HIVâHCV co-infected patients: ANRS Co13 Hepavih, France, 2006â2008. Journal of Viral Hepatitis.
Crossref
J. J. WEISS, N. BRÄU, A. STIVALA, T. SWAN & D. FISHBEIN. (2009) Review article: adherence to medication for chronic hepatitis C - building on the model of human immunodeficiency virus antiretroviral adherence research. Alimentary Pharmacology & Therapeutics 30:1, pages 14-27.
Crossref
J. J. WEISS, L. BHATTI, D. T. DIETERICH, B. R. EDLIN, D. A. FISHBEIN, M. B. GOETZ, K. YU & G. J. WAGNER. (2008) Hepatitis C patients’ self-reported adherence to treatment with pegylated interferon and ribavirin. Alimentary Pharmacology & Therapeutics 28:3, pages 289-293.
Crossref
Amparo Escudero, Felicidad Rodríguez, Miguel A Serra, Juan A del Olmo, Francisco Montes & José M Rodrigo. (2008) Pegylated α-interferon-2a plus ribavirin compared with pegylated α-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: Prospective, non-randomized study. Journal of Gastroenterology and Hepatology 23:6, pages 861-866.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.